Skip to content


  • Erratum
  • Open Access

Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis

  • 1, 10Email author,
  • 2,
  • 1,
  • 3,
  • 4,
  • 5,
  • 5,
  • 4,
  • 6,
  • 2,
  • 7,
  • 7,
  • 8 and
  • 2, 9Email author
Contributed equally
Arthritis Research & Therapy201719:11

  • Received: 6 January 2017
  • Accepted: 6 January 2017
  • Published:

The original article was published in Arthritis Research & Therapy 2016 18:294


Unfortunately, after publication of this article [1], it was noticed that the name of Gianfranco Ferraccioli was incorrectly spelled as Gianfranco Ferraciolli. The corrected author list can be seen above and the original article has been updated to correct this error.



Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Université Paris 06, AP-HP St-Antoine hospital, Rheumatology Department, INSERM UMRS_938, DHU i2B, Paris, France
Université Paris-Sud, AP-HP Hôpitaux Universitaires Paris-Sud, Rheumatology Department, Center for Immunology of Viral Infections and Autoimmune Diseases INSERM U1184, Le Kremlin Bicêtre, France
Biological Immunology Department, ERTICa Research Group, Clermont-Ferrand University Hospital, Clermont-Ferrand, EA4677, France
Rheumatology Department, Catholic University of the Sacred Heart, Roma, Italy
NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
Rheumatology Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
AP-HP Bicêtre Hospital, Biological Immunology Department, INSERM U1184, Le Kremlin Bicêtre, France
Department of Rheumatology - Hôpital Cochin, Paris Descartes University, Assistance Publique - Hôpitaux de Paris, INSERM (U1153), Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France
Service de Rhumatologie, Hôpital de Bicêtre, 78 rue du Général Leclerc, Le Kremlin Bicêtre, 94275, France
Service de Rhumatologie, Hôpital Saint-Antoine, 184 rue du Faubourg Saint-Antoine, Paris, 75012, France


  1. Sellam J, Rivière E, Courties A, Rouzaire PO, Tolusso B, Vital EM, Emery P, Ferraccioli G, Soubrier M, Ly B, Hendel Chavez H, Taoufik Y, Dougados M, Mariette X. Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. Arthritis Res Ther. 2016;18:294. ArticlePubMedPubMed CentralGoogle Scholar


© The Author(s). 2017